# US 2017/0281660 A1 · Topical composition for reducing pathogen binding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281660 A1
- Document ID: US20170281660A1
- Status: Published application
- Kind: A1
- Application number: 15/475,938
- Filed: 2017-03-31
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: GOJO Industries, Inc.
- Applicants: GOJO Industries, Inc.
- Inventors: Carrie Anne Zapka; Amanda J. Copeland; Abel Saud
- Web page: https://patentgrep.com/patent/US20170281660A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 8/73: Polysaccharides
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/716: Glucans
- A61K 31/721: Dextrans
- A61K 31/733: Fructosans, e.g. inulin
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/06: Fungi, e.g. yeasts
- A61K 38/28: Insulins
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61Q 19/10: Washing or bathing preparations
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method of reducing pathogen binding on skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more prebiotic and at least one carrier.

## Claims

### Claim 1

A topical composition for reducing pathogen binding on a surface, said composition comprising:
an active ingredient; and
at least one carrier, wherein said active ingredient comprises one or more of a prebiotic material, a probiotic material, and a synbiotic material, wherein said topical composition reduces pathogen binding on a surface by a statistically significant amount.

### Claim 2 (depends on 1)

The topical composition of claim 1, wherein said one or more prebiotic includes at least one of a saccharide, oligofructose, polydextrose, sugar alcohol, glucan, mannan, and inulin.

### Claim 3 (depends on 2)

The topical composition of claim 2, wherein said saccharide is at least one of fructooligosaccharide and galactooligosaccharide.

### Claim 4 (depends on 1)

The topical composition of claim 1, wherein said active ingredient includes a mixture of fructooligosaccharide and inulin.

### Claim 5 (depends on 1)

The topical composition of claim 1, wherein said probiotic material includes one or more of a bacteria, a bacteria derivative, a yeast, and a fungus.

### Claim 6 (depends on 5)

The topical composition of claim 5, wherein said bacteria includes one or more of Lactobacillus, Streptococcus, Escherichia, Corynebacteria, Lactococcus, Enterococcus, Fusobacterium, Streptomyces, Leuconostoc, Micrococcus, Bifidobacterium, Propionibacterium, Pediococcus, Staphylococcus, and Bacillus.

### Claim 7 (depends on 1)

The topical composition of claim 1, wherein said active ingredient comprises α-gluco-oligosaccharide, fructo-oligosaccharide and inactivated Lactobacillus.

### Claim 8 (depends on 1)

The topical composition of claim 1, wherein said active ingredient if Bacillus ferment.

### Claim 9 (depends on 1)

The topical composition of claim 1, wherein said carrier includes one or more of a base cleanser, a sanitizer, serum, and lotion.

### Claim 10 (depends on 1)

The topical composition of claim 1, wherein said surface is skin.

### Claim 11 (depends on 1)

The topical composition of claim 1, wherein said topical composition comprises 0.005 to 10 weight percent active ingredient.

### Claim 12 (depends on 1)

The topical composition of claim 1, wherein said topical composition comprises about 1.0 to 5.0 weight percent active ingredient.

### Claim 13 (depends on 1)

The topical composition of claim 1, wherein the application of said topical composition reduces pathogen binding on a surface by at least 5%.

### Claim 14 (depends on 1)

The topical composition of claim 1, wherein the application of said topical composition reduces pathogen binding on a surface by at least 10%.

### Claim 15

A method of reducing pathogen binding on a surface, said method comprising the steps of:
cleaning a surface with at least one of a cleanser and a sanitizer; and
applying a topical composition to the surface, wherein said topical composition is comprised of an active ingredient and at least one carrier, said active ingredient comprising one or more of a prebiotic material, a probiotic material, and a synbiotic material, wherein the application of said topical composition reduces pathogen binding on a surface by a statistically significant amount.

### Claim 16 (depends on 15)

The method of claim 15, wherein said surface is skin.

### Claim 17 (depends on 15)

The method of claim 15, wherein said prebiotic material includes at least one of a saccharide, oligofructose, polydextrose, sugar alcohol, glucan, mannan, and inulin.

### Claim 18 (depends on 17)

The method of claim 17, wherein said saccharide is at least one of fructooligosaccharide and galactooligosaccharide.

### Claim 19 (depends on 15)

The method of claim 15, wherein said topical composition include a mixture of fructooligosaccharide and inulin.

### Claim 20 (depends on 15)

The method of claim 15, wherein said probiotic material includes one or more of bacteria, bacteria derivative, yeast, and fungus.

### Claim 21 (depends on 20)

The method of claim 20, wherein said bacteria includes one or more of Lactobacillus, Streptococcus, Escherichia, Lactococcus, Enterococcus, Corynebacterium, Fusobacterium, Streptomyces, Leuconostoc, Micrococcus, Bifidobacterium, Propionibacterium, Pediococcus, Staphylococcus, and Bacillus.

### Claim 22 (depends on 15)

The method of claim 15, wherein said active ingredient comprises α-gluco-oligosaccharide, fructo-oligosaccharide and inactivated Lactobacillus.

### Claim 23 (depends on 15)

The method of claim 15, wherein said active ingredient comprises a blend of inulin and fructo-oligosaccharide.

### Claim 24 (depends on 15)

The method of claim 15, wherein said active ingredient if Bacillus ferment.

### Claim 25 (depends on 15)

The method of claim 15, wherein said carrier includes one or more of a base cleanser, a sanitizer, serum, and lotion.

### Claim 26 (depends on 25)

The method of claim 25, wherein said carrier is a sanitizer and has an alcohol content between 50 and 80 wt %.

### Claim 27 (depends on 15)

The method of claim 15, wherein said topical composition has a pH between 2.5 and 9.0.

### Claim 28 (depends on 15)

The method of claim 15, wherein said topical composition comprises 0.005 to 10 weight % active ingredient.

### Claim 29 (depends on 28)

The method of claim 28, wherein said topical composition comprises about 1.0 to 5.0 weight % active ingredient.

### Claim 30 (depends on 15)

The method of claim 15, wherein the application of said topical composition reduces pathogen binding on a surface by at least 5%.

### Claim 31 (depends on 15)

The method of claim 15, wherein the application of said topical composition reduces pathogen binding on a surface by at least 10%.
